H1B Report
Side-by-side comparison

Regeneron Pharmaceuticals, Inc. vs WIPRO LIMITED

A direct H-1B sponsorship comparison built from the same DOL Labor Condition Application data that drives every page on H1B Report. Total filings, outcome rates, top occupations and yearly demand side-by-side.

Entity A
Regeneron Pharmaceuticals, Inc.
NYRank #FEIN 13-3444607
Entity B
WIPRO LIMITED
NJRank #6FEIN 98-0154401

Key metrics

All percentages are share of total LCAs filed by each sponsor.

MetricRegeneron Pharmaceuticals, Inc.WIPRO LIMITED
Total filings1,16672,392
Certified %97.17%91.61%
Denied %0.51%0.37%
Withdrawn %1.20%1.37%
Cert-withdrawn %1.11%6.64%
Rank#6
Active yearsFY2010–FY2026FY2010–FY2026
Worksite stateNYNJ

Outcomes — Regeneron Pharmaceuticals, Inc.

DOL case-status mix.

Outcome breakdown: Certified 97.2%, Cert-withdrawn 1.1%, Withdrawn 1.2%, Denied 0.5%
Outcome breakdown
OutcomeShare
Certified97.2%
Cert-withdrawn1.1%
Withdrawn1.2%
Denied0.5%
Certified97.2%
Cert-withdrawn1.1%
Withdrawn1.2%
Denied0.5%

Outcomes — WIPRO LIMITED

DOL case-status mix.

Outcome breakdown: Certified 91.6%, Cert-withdrawn 6.6%, Withdrawn 1.4%, Denied 0.4%
Outcome breakdown
OutcomeShare
Certified91.6%
Cert-withdrawn6.6%
Withdrawn1.4%
Denied0.4%
Certified91.6%
Cert-withdrawn6.6%
Withdrawn1.4%
Denied0.4%

Yearly filing volume

Year-over-year H-1B demand for each sponsor.

Regeneron Pharmaceuticals, Inc.
Time series: 17 points from FY2010 to FY2026
Time series
PeriodValue
FY201051
FY201137
FY201240
FY201344
FY201443
FY201539
FY201647
FY201762
FY201880
FY201999
FY202024
FY202119
FY202224
FY202342
FY2024130
FY2025159
FY2026226
WIPRO LIMITED
Time series: 17 points from FY2010 to FY2026
Time series
PeriodValue
FY20103,039
FY20113,025
FY20127,031
FY20136,574
FY20148,104
FY201511,824
FY201610,254
FY20175,012
FY20186,067
FY20194,154
FY202094
FY2021128
FY202297
FY2023554
FY20242,296
FY20252,289
FY20261,850

Top 5 occupations — Regeneron Pharmaceuticals, Inc.

Top 5 occupations — WIPRO LIMITED

Swap an entity
Replace either sponsor above without losing the comparison. 2-way for now; 3+ comparison coming soon.